BSE Live
Apr 13, 15:06Prev. Close
1000.65
Open Price
990.00
Bid Price (Qty.)
999.95 (126)
Offer Price (Qty.)
1001.45 (1)
NSE Live
Apr 13, 15:06Prev. Close
1000.00
Open Price
993.00
Bid Price (Qty.)
1000.80 (22)
Offer Price (Qty.)
1001.25 (15)
| Cash Flow of Strides Pharma Science (in Rs. Cr.) | Dec 09 | Dec 08 | Dec 07 | Dec 06 | Dec 05 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 116.55 | 4.44 | -118.03 | 41.75 | 48.69 | |
| Net CashFlow From Operating Activities | -11.77 | 94.88 | 53.02 | -16.82 | 63.40 | |
| Net Cash Used In Investing Activities | -94.32 | -112.19 | -642.33 | -56.42 | -144.38 | |
| Net Cash Used From Financing Activities | 118.44 | -92.43 | 693.58 | 11.97 | 141.38 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.01 | 3.79 | -1.57 | 1.30 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 12.36 | -109.74 | 108.06 | -61.27 | 61.70 | |
| Cash And Cash Equivalents Begin of Year | 6.88 | 115.41 | 7.35 | 70.18 | 8.48 | |
| Cash And Cash Equivalents End Of Year | 19.23 | 5.66 | 115.41 | 7.35 | 70.18 |
18.03.2026
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
26.12.2025
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth